Ibutin (Trimebutine Maleate)

Ibutin (trimebutine maleate) acts on gastrointestinal motility disorders and is indicated for the following conditions:

• Irritable bowel syndrome: alleviates abdominal pain and irregular bowel habits by normalizing motility.
• Functional dyspepsia: reduces upper abdominal discomfort and fullness through motility regulation.
• Gastrointestinal motility disorders: improves transit and reduces symptoms associated with delayed or uncoordinated gut movement.

• Trimebutine maleate modulates gastrointestinal motility by acting as a peripheral μ‑opioid receptor agonist and antagonist. This dual activity stabilizes abnormal motility patterns, enhancing coordinated peristalsis and reducing spasm. The drug also influences enteric nervous system signaling, leading to normalization of gastric emptying and intestinal transit.

Trimebutine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild to moderate feeling of sickness.
• Abdominal pain or discomfort.
• Dry mouth.
• Headache.
• Dizziness.

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing.
• Hepatic dysfunction: jaundice, elevated liver enzymes.
• Cardiac arrhythmia: irregular heartbeat.

When prescribing or dispensing Ibutin, consider the following precautions.

• Medical supervision: use only under physician guidance, especially in chronic GI conditions.
• Hepatic impairment: adjust dose or monitor liver function in patients with liver disease.
• Renal impairment: exercise caution in severe kidney dysfunction.
• Pregnancy and lactation: safety not established; avoid unless benefit outweighs risk.
• Allergy: discontinue if signs of hypersensitivity appear.
• Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Trimebutine can interact with other medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase trimebutine plasma concentrations, raising toxicity risk.
• Other prokinetic agents (e.g., cisapride, metoclopramide): combined use can cause excessive gastrointestinal stimulation.
• Opioid analgesics: may antagonize opioid effects, altering pain control.

Moderate Interactions (Monitor Closely)

• Anticholinergic drugs (e.g., atropine, scopolamine): may reduce the prokinetic effect of trimebutine.
• Antidepressants affecting serotonin (e.g., SSRIs): monitor for gastrointestinal side‑effects.
• Diuretics: monitor electrolyte balance as GI motility changes can affect absorption.